Cargando…
BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma
Richter Transformation (RT) develops in CLL as an aggressive, therapy-resistant, diffuse large B cell lymphoma (RT-DLBCL), commonly clonally-related (CLR) to the concomitant CLL. Lack of available pre-clinical human models has hampered the development of novel therapies for RT-DLBCL. Here, we report...
Autores principales: | Fiskus, Warren, Mill, Christopher P., Perera, Dimuthu, Birdwell, Christine, Deng, Qing, Yang, Haopeng, Lara, Bernardo H., Jain, Nitin, Burger, Jan, Ferrajoli, Alessandra, Davis, John A., Saenz, Dyana T., Jin, Wendy, Coarfa, Cristian, Crews, Craig M., Green, Michael R., Khoury, Joseph D., Bhalla, Kapil N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410602/ https://www.ncbi.nlm.nih.gov/pubmed/33654205 http://dx.doi.org/10.1038/s41375-021-01181-w |
Ejemplares similares
-
Novel BET protein Proteolysis Targeting Chimera (BET-PROTAC) exerts superior lethal activity than Bromodomain Inhibitor (BETi) against post-myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells
por: Saenz, Dyana T., et al.
Publicado: (2017) -
Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells
por: Fiskus, Warren, et al.
Publicado: (2019) -
BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells
por: Saenz, Dyana T., et al.
Publicado: (2016) -
EVI1 dysregulation: impact on biology and therapy of myeloid malignancies
por: Birdwell, Christine, et al.
Publicado: (2021) -
Proteolysis targeting chimeras (PROTACs) come of age: entering the third decade of targeted protein degradation
por: Bond, Michael J., et al.
Publicado: (2021)